Alpha Tau Medical (DRTS) investor relations material

Company overview and business model

• Clinical-stage oncology therapeutics company developing localized alpha particle radiation therapy (Alpha DaRT) for solid tumors, targeting high unmet need indications and refractory tumors.

• Alpha DaRT technology aims to overcome the short range of alpha radiation, enabling precise tumor targeting with minimal damage to healthy tissue.

• Received regulatory approvals and designations in Israel, Japan, and the U.S., with ongoing pivotal and feasibility trials in multiple geographies.

• Holds exclusive rights to Alpha DaRT in core markets, with a robust patent portfolio of 140 issued patents and 240 pending applications globally.

• Plans for initial large-scale commercialization in the U.S. following regulatory milestones.

Financial performance and metrics

• As of December 31, 2025, had $12.2 million in cash and cash equivalents, and $64.7 million in restricted cash and short-term deposits.

• Shareholders' equity was $77.1 million, projected to increase to $174.0 million post-offering (assuming full $100 million raise at $8.08/share).

• Net tangible book value per share was $0.88, with expected dilution to new investors of $6.35 per share at the offering price.

• No dividends have been declared or paid; all earnings are retained for business development.

Use of proceeds and capital allocation

• Net proceeds will be used for general corporate purposes, R&D related to product candidates, manufacturing capabilities, and potential commercialization.

• Management has broad discretion over the application of proceeds, which may vary based on operational needs and market conditions.